Drugs / AZD3632
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07155226 | Jan 2026 → Feb 2029 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3632 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07155226 ↗ |
| Route | Oral | “AZD3632 will be administered orally.” NCT07155226 ↗ |